Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2024
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and OutcomesLuis E Aguirre, Akriti Jain, Somedeb Ball, et al.
Annals of Hematology|April 18, 2024
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CMLAkriti G Jain, Quinto Gesiotto, Somedeb Ball, et al.
Hematological Oncology|May 16, 2026
Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid LeukemiaGeorgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, et al.
Leukemia Research|June 19, 2022
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center databaseNoa Rippel, Douglas Tremblay, Nicole Zubizarreta, et al.
Leukemia Research|June 3, 2021
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional databaseDouglas Tremblay, Lukas Ronner, Nikolai Podoltsev, et al.
Haematologica|February 1, 2024
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemiaAkriti G Jain, Somedeb Ball, Luis Aguirre, et al.
Leukemia|May 5, 2023
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromesLuis E Aguirre, Najla Al Ali, David A Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia VeraAlexander Coltoff, Ruben Mesa, Jason Gotlib, et al.
Blood Neoplasia|June 2, 2025
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasmZhuoer Xie, Najla Al Ali, Ling Zhang, et al.
Leukemia Research|May 15, 2020
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancyChetasi Talati, Aaron D Goldberg, Amanda Przespolewski, et al.
Pageof 6